Our Clients
While the needs of each client differ, the fundamentals of creative conception, strategic planning, professional execution and results that return the client’s investment define every project. This commitment is underscored not only by the number of companies which MCS has supported since 1985, but also by the long tenure of our relationships with many of these clients.
 |
Adams Respiratory Therapeutics |
|
 |
Auxilium Pharmaceuticals |
|
 |
BD |
|
 |
CSL Behring |
|
 |
 |
Genentech |
 |
Qforma |
|
 |
Regeneron Pharmaceuticals |
|
 |
Schering-Plough |
|
 |
Synergetics USA |
Genentech
Profile
Since 1994, MCS has been the agency of record for Genentech's lytics franchise, including Activase® or t-PA, the first FDA-approved treatment for acute ischemic stroke within three hours of symptom onset; and TNKase®, a single-bolus thrombolytic for the treatment of heart attack.
MCS also handles product communication support for Raptiva® (efalizumab), a humanized therapeutic antibody designed to selectively and reversibly block the activation, reactivation and trafficking of T-cells that lead to the development of psoriasis.
Genentech is a leading biotechnology company that discovers, develops, manufactures, and commercializes biotherapeutics for significant unmet medical needs. A considerable number of the currently approved biotechnology products originated from or are based on Genentech science. Genentech manufactures and commercializes multiple biotechnology products and licenses several additional products to other companies.
For more information on Genentech, Inc., please visit the company's web site at www.gene.com.